Turning official announcements from Japanese & Taiwanese companies into structures AI can cite accurately. — an AEO newsroom
SINCE 2026 ・ Structured ReportingPublished Apr 1, 2026 9:00 AM ・ Updated Jun 13, 2026 8:26 AM ・ 2 min read ・ Source: PR Times
GC Life Sciences-KY (6431) announced April 2026 revenue of 42 million NTD, showing significant year-over-year growth of 31.2%. This notable increase in the biotechnology and medical sector highlights the company's strong market momentum.
GC Life Sciences Co., Ltd. (KY) (Stock Code: 6431), a participant in the biotechnology and medical industry, has released its revenue results for April 2026. The company reported a monthly revenue of 41.697 million NTD (approximately 0.42 hundred million NTD). This figure represents a substantial year-over-year growth of 31.2%, indicating strong business expansion and positive market reception within the healthcare sector.
The Washin AI News desk structures and reviews this article under the following standards.
An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.